(new: more details and background)

FRANKFURT (dpa-AFX) - Fresenius shares successfully bucked the negative trend in the DAX on Tuesday. The shares of the Bad Homburg-based company climbed to their highest level in around two months as the DAX leader with a plus of up to 3.8 percent.

The evening before, Fresenius announced the US market launch of the biosimilar Tyenne. This is a copycat product of the previously patent-protected antibody Tocilizumab against various autoimmune diseases.

According to DZ Bank expert Sven Kürten, the market launch comes somewhat earlier than he had expected. The news shows that Fresenius is still on a very good path. However, he does not see any direct impact on his profit forecasts.

In addition, Fresenius apparently sent analysts positive signals about the course of the first quarter, which will be reported on May 8. The year has apparently started well and leaves room for the annual targets, wrote analyst Marianne Bulot from Bank of America. The capital market day of the subsidiary Helios in June will be decisive for the share price performance. Bulot expects the outlook to be upgraded then./ag/ajx/jha/